Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

Annals of Neurology

Volumn 50, Issue 2, 2001, Pages 150-156

  Itoh, Nobuo ^a,b   Arai, Hiroyuki ^a   Urakami, Katsuya ^b   Ishiguro, Koichi ^a   Ohno, Hideto ^c   Hampel, Harald ^d   Buerger, Katharina ^e   Wiltfang, Jens ^f   Otto, Markus ^g   Kretzschmar, Hans ^h   Moeller, Hans Juergen ^e   Imagawa, Masaki ^a   Kohno, Hideki ^e   Nakashima, Kenji ^c   Kuzuhara, Shigeki ^d   Sasaki, Hidetada ^a   Imahori, Kazutomo ^a  

^a MIE UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d MITSUBISHI KASEI INST OF LIFE SCI   (Japan)

^e UNIVERSITY OF MUNICH   (Germany)

^f Amagasaki Kita Eijinkai Clinic   (Japan)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; SERINE; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION;

EID: 0034899223     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.1054     Document Type: Article

References (29)

1. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
2. Diagnosis of Alzheimers disease
3. Concensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's disease
4. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
5. Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: A longitudinal study
6. CSF tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls
7. Longitudinal study of cerebrospinal fluid levels of tau. Aß1-40, and Aß1-42(43) in Alzheimer's disease: A study in Japan
8. 42in the cerebrospinal fluid of patients with Alzheimer's disease
9. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay
10. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
11. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia
12. Disturbed consciousness and asthma
13. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
14. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy
15. CSF phoshorylated tau protein and mild cognitive impairment: A prospective study
16. Corticobasal degeneration, a clinical study of 36 cases
17. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop
18. Diagnostic criteria for sporadic Creutzfeldt-Jacob disease
19. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
20. Consensus guideline for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop
21. Clinical and neuropathological criteria for frontotemporal dementia
22. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
23. Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites
24. Apolipoprotein E genotyping by one-stage PCR
25. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization
26. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients
27. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylatlon
28. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: Tau pathologies with exclusively "exon 10" isoforms
29. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau